|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:acquisition
|
gptkb:Ariad_Pharmaceuticals
gptkb:Med_Immune
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:awards
|
Top Employer Global 2021
Best Workplaces 2020
Global Health Awards 2021
Pharma Times Awards 2020
Sustainability Awards 2021
|
|
gptkbp:capital
|
$140 billion (2021)
|
|
gptkbp:ceo
|
gptkb:Pascal_Soriot
|
|
gptkbp:clinical_trial
|
Phase III trials
Phase I trials
Phase II trials
|
|
gptkbp:collaborations
|
government agencies
non-profit organizations
academic institutions
scientific research organizations
|
|
gptkbp:employees
|
70,600 (2020)
|
|
gptkbp:founded
|
gptkb:1999
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_England
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Astra Zeneca PLC
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
over 10,000 patents
|
|
gptkbp:is_vulnerable_to
|
gptkb:Astra_Zeneca/_Oxford_vaccine
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Oxford_University
gptkb:Pfizer
gptkb:Merck_&_Co.
|
|
gptkbp:philanthropy
|
gptkb:Astra_Zeneca_Young_Health_Programme
community engagement programs
education and training initiatives
healthcare access initiatives
COVID-19 vaccine donations
|
|
gptkbp:products
|
vaccines
|
|
gptkbp:research
|
gptkb:Mene_Pangalos
|
|
gptkbp:research_and_development
|
oncology
neuroscience
immunology
cardiovascular
respiratory
|
|
gptkbp:revenue
|
$37 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:LSE
|
|
gptkbp:subsidiary
|
gptkb:Astra_Zeneca_UK_Limited
|
|
gptkbp:sustainability
|
diversity and inclusion initiatives
sustainable sourcing
carbon neutrality by 2025
zero waste to landfill by 2025
water neutrality by 2030
|
|
gptkbp:symbol
|
AZN
|